Loading patent…
AssigneeThe Johns Hopkins University
InventorsMichela Gallagher, Rebecca Haberman, Ming Teng Koh
Estimating the term…
The invention relates to methods and compositions for improving cognitive function by using a combination of a synaptic vesicle protein 2A (SV2A) inhibitor and an acetylcholinesterase inhibitor (AChEI) or their pharmaceutically acceptable salts, hydrates, solvates, polymorphs thereof. In particular, it relates to the use of a combination of an SV2A inhibitor and an AChEI in treating a central nervous system disorder with cognitive impairment in a subject in need or at risk thereof, including, without limitation, subjects having or at risk for age-related cognitive impairment, Mild Cognitive Impairment (MCI), dementia, Alzheimer's Disease (AD), prodromal AD, post traumatic stress disorder (PTSD), schizophrenia, amyotrophic lateral sclerosis (ALS), and cancer-therapy-related cognitive impairment.
A method for treating a central nervous system (CNS) disorder with cognitive impairment in a subject in need or at risk thereof, the method comprising the step of administering to said subject a therapeutically effective amount of a synaptic vesicle protein 2A (SV2A) inhibitor or a pharmaceutically acceptable salt, hydrate, solvate, polymorph thereof and a therapeutically effective amount of an acetylcholinesterase inhibitor (AChEI) or a pharmaceutically acceptable salt, hydrate, solvate or polymorph thereof.
A method of increasing the therapeutic index of an AChEI or a pharmaceutically acceptable salt, hydrate, solvate or polymorph thereof in a method of treating a central nervous system (CNS) disorder with cognitive impairment in a subject in need or at risk thereof, comprising administering an SV2A inhibitor or a pharmaceutically acceptable salt, hydrate, solvate or polymorph thereof in combination with an AChEI or a pharmaceutically acceptable salt, hydrate, solvate or polymorph thereof to said subject.
A method of increasing the therapeutic index of an SV2A inhibitor thereof in a method of treating a central nervous system (CNS) disorder with cognitive impairment in a subject in need or at risk thereof, comprising administering an SV2A inhibitor in combination with an AChEI to said subject.
A pharmaceutical composition comprising an SV2A inhibitor and an AChEI or their pharmaceutically acceptable salts, hydrates, solvates, or polymorphs, in separate dosage form packaged together or in a unit dosage form.
Dependencies are inferred from the claim text.